Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
18.60
Dollar change
-2.29
Percentage change
-10.96
%
IndexRUT P/E- EPS (ttm)-1.38 Insider Own28.90% Shs Outstand9.22M Perf Week-12.10%
Market Cap172.61M Forward P/E- EPS next Y-1.84 Insider Trans0.00% Shs Float6.60M Perf Month27.48%
Income-12.75M PEG- EPS next Q-0.44 Inst Own24.12% Short Float4.04% Perf Quarter9.48%
Sales19.85M P/S8.70 EPS this Y-238.67% Inst Trans- Short Ratio1.63 Perf Half Y42.86%
Book/sh2.44 P/B7.61 EPS next Y27.43% ROA-19.46% Short Interest0.27M Perf Year88.83%
Cash/sh3.83 P/C4.85 EPS next 5Y- ROE-45.14% 52W Range7.10 - 24.00 Perf YTD82.89%
Dividend Est.- P/FCF- EPS past 5Y-22.25% ROI-42.99% 52W High-22.50% Beta0.82
Dividend TTM- Quick Ratio1.83 Sales past 5Y158.87% Gross Margin16.92% 52W Low161.97% ATR (14)1.71
Dividend Ex-Date- Current Ratio1.98 EPS Y/Y TTM59.55% Oper. Margin-74.91% RSI (14)52.20 Volatility8.99% 9.51%
Employees100 Debt/Eq0.35 Sales Y/Y TTM-23.32% Profit Margin-64.24% Recom1.00 Target Price29.75
Option/ShortYes / Yes LT Debt/Eq0.28 EPS Q/Q-139.29% Payout- Rel Volume1.20 Prev Close20.89
Sales Surprise6.06% EPS Surprise-158.18% Sales Q/Q30.67% EarningsMay 29 BMO Avg Volume163.83K Price18.60
SMA206.47% SMA508.91% SMA20038.28% Trades Volume196,278 Change-10.96%
Date Action Analyst Rating Change Price Target Change
Jul-16-24Reiterated Maxim Group Buy $25 → $30
Dec-22-22Initiated Maxim Group Buy $11
Jul-18-22Resumed Oppenheimer Outperform $7
Sep-23-20Initiated BTIG Research Buy $6
Nov-28-16Initiated Aegis Capital Buy $11
Aug-17-16Initiated Wells Fargo Outperform
Apr-16-14Initiated Oppenheimer Outperform $25
Jul-16-24 07:30AM
Jul-15-24 07:38AM
07:38AM
07:00AM
May-29-24 02:40PM
11:53AM Loading…
11:53AM
08:15AM
07:12AM
07:00AM
May-22-24 08:00AM
Apr-25-24 08:00AM
Apr-17-24 07:24AM
Mar-25-24 09:55AM
08:50AM
Mar-21-24 11:54AM
08:25AM Loading…
08:25AM
07:25AM
07:00AM
Mar-14-24 08:00AM
Mar-06-24 08:46AM
Feb-12-24 07:00AM
Feb-05-24 08:00AM
Jan-15-24 09:55AM
Jan-09-24 06:21PM
08:48AM
07:00AM
Dec-28-23 07:00AM
Dec-21-23 08:00AM
Dec-13-23 09:55AM
Nov-27-23 09:55AM
07:12AM Loading…
Nov-21-23 07:12AM
07:02AM
07:00AM
Nov-14-23 08:02AM
Nov-13-23 07:00AM
Nov-08-23 07:00AM
Oct-11-23 06:00AM
Oct-09-23 07:34AM
Oct-03-23 01:20PM
Sep-29-23 08:00AM
Sep-26-23 07:00AM
Sep-21-23 06:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:15PM
04:11PM
04:03PM
04:02PM
04:01PM
Aug-07-23 08:00AM
Aug-01-23 07:30AM
Jul-11-23 06:05AM
Jul-10-23 07:30AM
Jul-03-23 07:00AM
Jun-28-23 06:51AM
Jun-14-23 08:00AM
Jun-01-23 06:07AM
May-30-23 08:15AM
07:08AM
07:00AM
May-12-23 08:00AM
May-09-23 07:30AM
Apr-26-23 08:00AM
Apr-19-23 11:40AM
Mar-18-23 08:26AM
08:22AM
Mar-16-23 08:35AM
07:10AM
07:00AM
Mar-09-23 10:00AM
Mar-06-23 07:00AM
Mar-02-23 08:47AM
Feb-23-23 08:00AM
Feb-16-23 05:31AM
Feb-07-23 04:01PM
Feb-03-23 10:30AM
Jan-13-23 10:19AM
Jan-06-23 07:19AM
Dec-30-22 05:26AM
Dec-29-22 01:46PM
Dec-23-22 08:00AM
Dec-20-22 08:00AM
Dec-19-22 07:00AM
Dec-13-22 05:30AM
Dec-05-22 04:05PM
Nov-15-22 08:15AM
07:00AM
Nov-09-22 08:00AM
Nov-03-22 08:00AM
Oct-25-22 07:00AM
Oct-18-22 07:00AM
Oct-07-22 06:00AM
Sep-22-22 08:02AM
Sep-20-22 07:00AM
Sep-12-22 08:00AM
Aug-23-22 07:00AM
Aug-15-22 06:08AM
Aug-09-22 08:45AM
07:30AM
Aug-08-22 04:05PM
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.